Nicholas Bellos

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation

Joseph J. Eron, John Bartlett, Jorge Santana et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 40 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

Kathleen Squires, Benjamin Young, Edwin DeJesus et al. · HIV Clinical Trials · 2010 · 25 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure

Pablo Tebas, Nicholas Bellos, Christopher Lucasti et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2008 · 24 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients

Christine Katlama, Nicholas Bellos, Beatriz Grinsztejn et al. · Journal of the International AIDS Society · 2008 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12